Recent Research Analysts’ Ratings Updates for Zenas BioPharma (ZBIO)

A number of firms have modified their ratings and price targets on shares of Zenas BioPharma (NASDAQ: ZBIO) recently:

• 5/16/2026 – Zenas BioPharma was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/15/2026 – Zenas BioPharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.
• 5/14/2026 – Zenas BioPharma had its price target raised by Morgan Stanley from $21.00 to $22.00. They now have an “equal weight” rating on the stock.
• 5/14/2026 – Zenas BioPharma had its “buy” rating reaffirmed by Citigroup Inc..
• 3/27/2026 – Zenas BioPharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/21/2026 – Zenas BioPharma was downgraded by Wall Street Zen from “hold” to “strong sell”.

Insiders Place Their Bets

In related news, Director Fairmount Funds Management Llc acquired 150,000 shares of the business’s stock in a transaction on Tuesday, March 31st. The stock was purchased at an average cost of $20.00 per share, for a total transaction of $3,000,000.00. Following the completion of the transaction, the director directly owned 2,359,025 shares of the company’s stock, valued at approximately $47,180,500. The trade was a 6.79% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Hongbo Lu acquired 3,768 shares of the business’s stock in a transaction on Tuesday, March 31st. The shares were bought at an average price of $18.63 per share, with a total value of $70,197.84. Following the completion of the transaction, the director directly owned 426,736 shares of the company’s stock, valued at approximately $7,950,091.68. The trade was a 0.89% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 273,768 shares of company stock worth $5,150,198 over the last three months. Insiders own 22.00% of the company’s stock.

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.